Mohammed Youssef

Dr. Mohammed Youssef


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2026 in European Journal of Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
MYMohammed Youssef
Mohammed Youssef
IBIsabella Bortolussi
Isabella Bortolussi
MEMohamed H. Eldessouki
Mohamed H. Eldessouki
HKHafsa Khan
Hafsa Khan
AUAsim Usman
Asim Usman
JJJaison John
Jaison John
Introduction: There is a large variety of intestinal foreign bodies, including sex toys, produce, and glass, and management depends on the object’s composition and location. We present a case of a fibrous foreign body causing complete colonic obstruction that was successfully treated using a novel balloon-assisted technique. Case description: A 30-year-old woman with no significant medical history presented with abdominal pain, constipation, nausea, and vomiting. Computed tomography (CT) imaging demonstrated a large faecal burden in the proximal colon with mucosal thickening and obstruction from a presumed fixed mass in the left colon. Colonoscopy revealed a foreign body completely occluding the descending colon lumen. Initial removal attempts using nets, snares, and grasping devices were unsuccessful, and surgery was consulted for possible hemicolectomy. In a final effort to avoid surgery, a 20 mm through-the-scope balloon dilator was advanced blindly through the fibrous obstruction. The balloon was inflated and retracted toward the colonoscope to fragment and sweep debris. Repeated passes removed substantial fibrous material. Mineral oil lavage was administered to lubricate the lumen and facilitate debris passage. The patient subsequently received 2 litres of polyethylene glycol. Repeat CT imaging showed near-complete resolution of obstruction. Pathology demonstrated acellular fibrous material with inflammatory cells. Discussion: Foreign body ingestion is common, yet refractory colonic impactions lack standardized management. This case demonstrates that balloon-assisted sweeping with adjunctive lavage can provide a safe, surgery-sparing alternative for complex colonic foreign body obstruction.

1 April 2026 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
HAHazem Abosheaishaa
Hazem Abosheaishaa
MYMohammed Youssef
Mohammed Youssef
MEMohamed H. Eldesouki
Mohamed H. Eldesouki
MEMohamad Elgozair
Mohamad Elgozair
MIMina Iskander
Mina Iskander
MRMadhavi Reddy
Madhavi Reddy
Background: Peptic ulcer bleeding remains a significant cause of non-variceal upper gastrointestinal bleeding (NVUGIB). While over-the-scope clips (OTSC) are increasingly used as rescue therapy, their efficacy as first-line treatment remains unclear. The aim of this study is to evaluate the efficacy and safety of OTSC compared to standard endoscopic therapy (SET) as a first-line treatment in patients with bleeding peptic ulcer disease (PUD). Methods: A systematic literature search was conducted across MEDLINE, Embase, Scopus, Web of Science, and Cochrane databases up to March 13, 2026. Studies comparing OTSC and SET in bleeding PUD were included. Primary outcome was Clinical Success. Secondary outcomes included primary and technical success, need for surgery or re-therapy, mortality, hospital stay, and adverse events. Meta-analyses were performed using a random-effects model. Results: Six studies [3 randomized controlled trials (RCTs), 3 observational] comprising 454 patients were included. OTSC significantly improved clinical success [risk ratio (RR) =1.16, 95% confidence interval (CI): 1.06–1.27, P=0.002]. OTSC also significantly reduced overall bleeding (RR =0.46, 95% CI: 0.25–0.82, P=0.009). No statistically significant differences were observed in primary success, technical success, 7- or 30-day rebleeding, need for re-therapy, surgical intervention, in-hospital mortality, total mortality, adverse events, or hospital stay. Conclusions: OTSC is associated with significantly higher clinical success and lower overall bleeding rates compared to SET in bleeding PUD. Secondary outcomes, including rebleeding, re-intervention, and mortality, trended in favour of OTSC but did not reach statistical significance, likely reflecting limited power. These findings support OTSC as a promising first-line option. Further large-scale RCTs are warranted to confirm these results and guide clinical implementation.

11 May 2025 in ASIDE Internal Medicine
Verified
Journal Article
Open access
AAAhmed Mohamed Ali Aref
Ahmed Mohamed Ali Aref
AAAhmed H. Abdelwahed
Ahmed H. Abdelwahed
ANAbdelrahman Nassar
Abdelrahman Nassar
MEMohamed Elshennawy
Mohamed Elshennawy
MMMaryam Massoud
Maryam Massoud
MAMostafa Alfishawy
Mostafa Alfishawy
Background: Living donor liver transplantation (LDLT) is a crucial therapeutic option for patients with end-stage liver disease in Egypt, where deceased donor grafts are scarce. This study aims to investigate the challenges and infectious complications associated with LDLT in Egypt. Methods: A comprehensive review of relevant literature was conducted, focusing on factors affecting donor selection, the prevalence of infections in recipients, and the impact of healthcare providers' knowledge on organ donation. The study included data on complications affecting donors and recipients in the context of LDLT. Results: The high prevalence of the hepatitis C virus and poverty in Egypt negatively impact the live donor pool. Lack of knowledge about liver donation, inadequate media coverage, and family pressure contribute to the low number of liver donors. Infectious complications play a significant role in the outcomes of LDLT, with bacterial infections being the most common. Donors also experience complications, with intraabdominal collections and pneumonia being the most frequent. Healthcare providers' knowledge and attitudes toward organ donation need improvement, and educational efforts should be tailored to the cultural and religious context. Conclusion: Addressing the challenges in donor selection, raising public awareness about organ donation, and improving healthcare providers' knowledge are essential steps toward optimizing LDLT outcomes in Egypt. Moreover, it is crucial to monitor and manage infectious complications in both donors and recipients to ensure the success of the transplantation process.

1 June 2026 in Annals of Translational Medicine
Verified
Journal Article
Open access
OAOmar Abdelhalim
Omar Abdelhalim
MYMohammed Youssef
Mohammed Youssef
SASawsan Al-Lababidi
Sawsan Al-Lababidi
MEMohamed Eldesouki
Mohamed Eldesouki
AMAhmed Mohamed
Ahmed Mohamed
HAHazem Abosheaishaa
Hazem Abosheaishaa
Patients with coexisting type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) represent a high-risk population with competing comorbidities, complex medication regimens, and overlapping inflammatory pathways. Although the role of sodium-glucose co-transporter-2 (SGLT2) inhibitors in managing type 2 diabetes is well-established, their impact on outcomes in diabetic patients with coexisting IBD remains unclear. This study aimed to investigate the association between SGLT2i use and hospitalization, intensive care unit (ICU) admission, mortality, IBD-related complications, and surgical procedures in diabetic patients with IBD. We conducted a retrospective cohort study using the TriNetX Global Collaborative Network. Cohort 1 comprised diabetic patients with IBD who received SGLT2 inhibitors with at least three dispensations within one year of IBD diagnosis, and Cohort 2 comprised diabetic patients with IBD never prescribed SGLT2i, matched on baseline characteristics, comorbidities, IBD-specific medications, and laboratory values, yielding 3,950 patients per cohort. Clinical outcomes were evaluated at 1 and 5 years following the index event. At 1 year, hospitalization, ICU admission, and mortality were significantly lower in Cohort 1 [risk ratio (RR): 0.886, P<0.001; RR: 0.851, P=0.03; and RR: 0.525, P<0.001, respectively]. Kaplan-Meier analysis demonstrated improved survival in Cohort 1 [94.27% vs. 88.76%, P<0.001; hazard ratio (HR): 0.490]. IBD-related complications and surgical procedures were also significantly reduced (RR: 0.879, P=0.004 and RR: 0.548, P=0.02, respectively). At 5 years, hospitalization, ICU admission, and mortality remained significantly lower in Cohort 1 (RR: 0.932, P=0.002; RR: 0.848, P=0.003; and RR: 0.545, P<0.001, respectively). Kaplan-Meier analysis continued to demonstrate improved survival in Cohort 1 (85.01% vs. 74.95%, P<0.001; HR: 0.532), whereas IBD-related complications and surgical procedures were numerically lower but no longer statistically significant (RR: 0.954, P=0.18 and RR: 0.741, P=0.15, respectively). SGLT2i therapy in diabetic patients with IBD was associated with reduced hospitalization, ICU admission, and mortality, with persistent benefits observed at both 1 and 5 years of follow-up. Reductions in IBD-related complications and surgical procedures were observed, particularly at 1 year. These findings suggest a potential disease-modifying role warranting further prospective investigation.

15 April 2026 in Cureus
Verified
Journal Article
Open access
MYMohammed Youssef
Mohammed Youssef
ABAndrea Brestel
Andrea Brestel
HKHafsa Khan
Hafsa Khan
AUAsim Usman
Asim Usman
JJJaison John
Jaison John
Herpes simplex virus esophagitis (HE) is a commonly observed disease in immunocompromised individuals, but is rare in immunocompetent individuals and often misdiagnosed due to overlapping features with other causes of esophagitis. Delay in diagnosis and appropriate treatment can lead to severe complications such as esophageal ulceration, resulting in bleeding, perforation, fistulas, food impaction, and strictures. We report a rare case of recurrent HE in an immunocompetent male initially misdiagnosed as Candida esophagitis. This case underscores the importance of considering HSV in the differential diagnosis of esophageal ulcerations, highlights the potential for recurrence in immunocompetent hosts, and emphasizes the need for accurate diagnosis, timely antiviral therapy, and patient education to prevent complications.

9 February 2026 in Research Square
Verified
Preprint
Open access
PDF file
MYMohammed Youssef
Mohammed Youssef
MEMohamed H. Eldesouki
Mohamed H. Eldesouki
HAHazem Abosheaishaa
Hazem Abosheaishaa
MEMohamed Elgozair
Mohamed Elgozair
MHMahmoud F. Hammad
Mahmoud F. Hammad
SESherif E Elhanafi
Sherif E Elhanafi
Introduction: Primary liver cancer remains a leading cause of cancer-related mortality worldwide, with Egypt representing a uniquely high-burden setting due to historically widespread hepatitis C virus infection. This study aimed to comprehensively evaluate long-term trends in the burden of Primary liver cancer in Egypt from 1990 to 2023, with particular emphasize on the impact of the national HCV elimination campaign, and project future trends through 2050. Methods: Data were obtained from the Global Burden of Disease 2023 database. Age-standardized incidence, mortality, prevalence, and disability-adjusted life years (DALYs) for Primary liver cancer were analyzed by sex and underlying etiology. Future projections to 2050 were generated using the GBD forecasting framework. Results: Between 1990 and 2023, age-standardized incidence, mortality, and DALY rates for PLC in Egypt declined overall, with the steepest reductions observed between 2014 and 2019, coinciding with nationwide HCV eradication efforts. However, a rebound in incidence and mortality was observed after 2019. HCV remained the leading cause of Primary liver cancer mortality throughout the study period, although its contribution declined substantially. Notably, nonalcoholic steatohepatitis surpassed hepatitis B as the second leading cause of Primary liver cancer mortality by 2023. Projections suggest that comprehensive control of viral and metabolic risk factors could reduce Primary liver cancer mortality by nearly half by 2050. Conclusion: Egypt’s HCV elimination campaign substantially reduced the burden of Primary liver cancer; however, long-term surveillance and integrated, multi-etiologic prevention strategies are essential to achieve durable reductions in Primary liver cancer burden.